The last time I wrote about 4D Molecular Therapeutics, Inc. (FDMT), it was in a Seeking Alpha article entitled “4d Molecular Therapeutics: Several Value Inflection Points To Watch In 2024.” In this ...

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) (CEO: ...

TOKYO and EMERYVILLE, Calif., July 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (FDMT) (CEO: David Kirn, ...

On Monday, 4D Molecular Therapeutics (NASDAQ:FDMT) shares saw its price target significantly raised by investment firm Jefferies, from $30.00 to $58.00, while the firm maintained its Buy rating. The ...

- Novel vector, 4D-C102, demonstrates superior performance compared to commonly used AAV1, AAV8, and AAV9 - - Fabry product candidate, 4D-310, is on track for anticipated clinical trial initiation in ...

眼科領域における遺伝子治療に4DMT社独自のアデノ随伴ウイルスベクターR100を使用するライセンス契約を締結 アステラス製薬株式会社（本社 : 東京、代表取締役社長 CEO : 岡村 直樹、以下「アステラス製薬」）と4D Molecular Therapeutics, Inc.（本社 : 米国 ...

Please provide your email address to receive an email when new articles are posted on . Astellas has gained the rights to utilize 4DMT’s R100 vector to deliver its unique genetic payloads. Astellas is ...